Methotrexate Accord

Methotrexate, the active ingredient in Methotrexate Accord, is an antimetabolite presented as a sterile injectable for intra‑arterial, intramuscular, and intrathecal use. It is employed in the management of rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and gestational trophoblastic disease.

GNH USA supplies Methotrexate Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, with distribution across Europe and other global markets, ensuring quality and regulatory compliance.

Methotrexate is used to treat diseases that involve abnormal cell proliferation or immune‑mediated inflammation. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell turnover and plaque formation. - Acute lymphoblastic leukemia: interferes with malignant lymphoblast replication. - Non‑Hodgkin lymphoma: impedes growth of lymphoma cells. - Gestational trophoblastic disease: promotes resolution of trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Fatigue - Mouth sores (stomatitis) - Elevated liver enzymes

Serious or Rare Side Effects: - Severe bone marrow suppression - Hepatotoxicity with fibrosis - Pulmonary fibrosis or pneumonitis - Life‑threatening infection

Before initiating Methotrexate, several safety considerations should be observed. - Pregnancy: contraindicated (Category X); avoid use in pregnant or nursing women. - Renal function: assess creatinine clearance and adjust or avoid if impaired. - Liver function: monitor transaminases regularly; discontinue if significant elevation. - Hematologic status: perform baseline and periodic complete blood counts. - Drug interactions: avoid concomitant high‑dose NSAIDs and live vaccines. - Store at controlled room temperature: keep in original container, protect from moisture and light.

Methotrexate can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Live vaccines: may cause severe infection. - High‑dose NSAIDs: increase methotrexate toxicity. - Sulfasalazine: additive bone‑marrow suppression. - Trimethoprim‑sulfamethoxazole: heightened myelosuppression. - Radiation therapy: enhanced tissue damage.

Moderate Interactions (Monitor Closely): - Penicillins: may raise methotrexate plasma levels. - Proton pump inhibitors: can affect renal clearance. - Azathioprine: combined immunosuppression risk. - Alcohol: may exacerbate liver toxicity.